Bard Financial Services Inc. Sells 875 Shares of Amgen Inc. (NASDAQ:AMGN)

Bard Financial Services Inc. lowered its holdings in Amgen Inc. (NASDAQ:AMGN) by 3.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 27,310 shares of the medical research company’s stock after selling 875 shares during the period. Bard Financial Services Inc.’s holdings in Amgen were worth $7,118,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Pathway Financial Advisers LLC increased its holdings in Amgen by 33,125.4% in the 3rd quarter. Pathway Financial Advisers LLC now owns 4,460,181 shares of the medical research company’s stock valued at $1,437,115,000 after buying an additional 4,446,757 shares during the period. International Assets Investment Management LLC boosted its position in shares of Amgen by 6,812.4% during the 3rd quarter. International Assets Investment Management LLC now owns 2,523,387 shares of the medical research company’s stock worth $8,130,610,000 after acquiring an additional 2,486,882 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in Amgen by 561.5% in the third quarter. Assenagon Asset Management S.A. now owns 1,539,733 shares of the medical research company’s stock valued at $496,117,000 after acquiring an additional 1,306,982 shares during the last quarter. Granite Bay Wealth Management LLC lifted its stake in Amgen by 9,058.1% during the second quarter. Granite Bay Wealth Management LLC now owns 756,460 shares of the medical research company’s stock worth $223,897,000 after purchasing an additional 748,200 shares during the last quarter. Finally, Nordea Investment Management AB lifted its position in shares of Amgen by 40.7% during the 4th quarter. Nordea Investment Management AB now owns 2,338,665 shares of the medical research company’s stock worth $609,526,000 after buying an additional 676,598 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on AMGN shares. Piper Sandler Companies restated an “overweight” rating and set a $310.00 price objective on shares of Amgen in a research report on Thursday. Barclays raised their price target on shares of Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. Redburn Partners dropped their target price on shares of Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft cut their target price on Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Finally, Robert W. Baird reiterated an “underperform” rating and issued a $215.00 target price on shares of Amgen in a report on Wednesday, September 25th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $318.83.

Amgen Price Performance

Shares of AMGN stock traded down $1.89 during trading hours on Monday, reaching $259.33. The stock had a trading volume of 1,468,309 shares, compared to its average volume of 2,221,936. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The firm has a market capitalization of $139.40 billion, a PE ratio of 33.20, a PEG ratio of 2.91 and a beta of 0.56. The stock’s fifty day simple moving average is $284.63 and its 200 day simple moving average is $310.47.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the prior year, the business earned $4.96 EPS. On average, equities research analysts predict that Amgen Inc. will post 19.53 EPS for the current year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a dividend of $2.38 per share. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a yield of 3.67%. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s payout ratio is presently 121.90%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.